RaQualia Pharma [4579]

Pipelines

Updated on 7 6, 2018

Completed
On planning
On going
Launch
Plan
Project Compound
(Generic name)
Indication Partnered party Discovery Pre-Clin, Clinical Studies NDA Approval Sales Territory Remarks
Phase 1 Phase 2 Phase 3
PotassiumCompetitive acid blocker
(P-CAB)
RQ-00000004
(Tegoprazan)
CJ-12420 [CJ HealthCare]
LXI-15028 [Luoxin Pharma]
RE/NERD -
Completed P1
USA
Japan
RE/NERD CJ HealthCare
Approval (July 2018)
Launch
2019
Korea Product name: K-CAB
CJ expects the potential market size of tegoprazan in Korea to be over 100 million dollars.
On going P1
China Re-contracted: CJ HealthCare => Luoxin Pharma
Market Size (China): 260 billion yen (2 billion 600 million USD) *Investigation of RaQualia
On planning P1
ROW ROW: Latin America, East European, Middle East
Taiwan
Southeast Asia
Related information
TRPM8 blocker RQ-00434739 Neuropathic pain -
On planning
Japan
P2X7 receptor antagonist RQ-00466479
AKP-23494954 [Asahi Kasei Pharma]
Neuropathic pain Asahi Kasei Pharma
On planning
Global Diabetic neuropathic medicine, herpes virus infective neuropathic medicine. It is conducting tests to establish long-term toxicity tests and industrial synthesis methods. Clinical trial schedule for people in 2019. [Reference]
Selective sodium channel blocker - - Maruho
On planning
Global
- Pain -
Discovery
Japan
Ion channel On Identity Test Pain XuanZhu Pharma
On going
China
- Gastrointestinal EA Pharma
Completed
Japan
protein-protein interaction inhibitor On Identity Test Pain Interprotein
On going
Japan
5-HT4 partial agonist RQ-00000010 Gastroparesis
Functional dyspepsia
Chronic Constipation
-
Completed P1
UK Mosapride's sales amount of peak tops is 21.2 billion yen (Japan)
Gastroparesis
Functional dyspepsia
ZTE Coming Biotech
Completed
China
Gastroparesis -
Investigator Clinical Trial
USA Collaboration with Virginia Commonwealth University (VCU) Parkinson's and Movement Disorders Center
RQ-00000009
AAT-009 [AskAt]
Alzheimer AskAt Global
5-HT2B antagonist RQ-00310941 IBS-D -
Completed P1
UK
ZTE Coming Biotech
Completed
China
Motilin receptor agonist RQ-00201894 Gastroparesis
Functional dyspepsia
Post - operative Ileus
-
Completed
Japan
Ghrelin receptor agonist RQ-00000005
(Capromorelin)
AT-002 [Aratana]
Weight loss, Anorexia: Dog Aratana Therapeutics
(Global (Animal))
Launch (October 2017)
USA Product name: Entyce®
Approval (2018)
Launch
2019
Europe
Weight loss, Anorexia: Cat
Long term toxicity test
USA
RQ-00433412 Anorexia associated with cancer -
On planning
Japan
Ziprasidone RQ-00000003
(Ziprasidone Hydrochloride Monohydrate)
ME2112 [Meiji Seika Pharma]
Schizophrenia, Bipolar disorder Meiji Seika Pharma
On going P3
NDA
2019
Launch
2020
Japan Market Size (Japan): 160 Billion Yen *Investigation of RaQualia
EP4 antagonist RQ-00000007
(Grapiprant)
AAT-007 [AskAt]
AT-001 [Aratana]
ARY-007 [Arrys]
Osteoarthritis: Dog Aratana Therapeutics
(Global (Animal))
Launch (January 2017)
USA Product name: Galliprant®
With this product Aratana makes strategic alliance with Elanco
Approval (January 2018)
Launch
2018
Europe
Cancer AskAt
(Global (Excluding animal))
On planning P1
USA Re-contracted: AskAt => Arrys Therapeutics (Global excluding China and Taiwan)
Development: Arrys affiliate Kyn Therapeutics
On going P1
China Re-contracted: AskAt => Ningbo Tai Kang Medical Technology
Development: Ningbo NewBay Medical Technology
Pain
Completed P2a
USA
On going P1
China Re-contracted: AskAt => RMX Biopharma
RQ-00000008
AAT-008 [AskAt]
AT-019 [Aratana]
Animal AskAt
(Global)
Development started (2018)
Global Re-contracted: AskAt => Aratana
Cancer
On planning P1
USA Re-contracted: AskAt => Arrys Therapeutics (Global excluding China and Taiwan)
China Re-contracted: AskAt => Ningbo NewBay Medical Technology
COX-2 Inhibitor RQ-00317076
AAT-076 [AskAt]
Acute Pain AskAt
(Global)
Completed P2a
USA
On planning P1
China Re-contracted: AskAt => RMX Biopharma

Other Pipelines

Updated on 3 3, 2018

Project Indication Partnered party Territory Remarks
CB2 antagonist AskAt
Dalbavancin MRSA Infections - Japan US product name: Dalvance
Anidulafungin Candida Infections - Japan US product name: Eraxis

Other Contracts

Updated on 7 9, 2018

Contractor Contract contents Remarks
H. Lundbeck A/S
(Denmark)
RaQualia Grants Patent License to H. Lundbeck Press release
Shire AG
(Swiss)
RaQualia Grants a Non-Exclusive Patent License to Shire AG For the Use of Ghrelin Receptor Agonist Press release

University Collaborative Research

Updated on 7 2, 2018

RaQualia Pharma Industry-Academia Collaborative Research Center

University Department Research theme Remarks
Nagoya University Faculty of Genome Dynamics, RIeM Exploration of selective blockers targeting DNA Polymerase eta Press release
Department of Biochemistry, Graduate School of Medicine Exploration of selective blockers targeting specific enzymes for treatment of refractory neuroblastoma Press release
Department of Pathology and Biological Responses, Graduate School of Medicine Exploration of selective blockers targeting connective tissue growth factors (CTGF) for treatment of malignant mesothelioma Press release
Department of Nephrology, Internal Medicine, Graduate School of Medicine Exploration of small molecule compounds inducing the secretion of cytokines and growth factors from adipose-derived stem cells Press release
Graduate School of Bioagricultural Sciences Antibody production by gene transfer method using chicken
Department of Cardiovascular Medicine Exploration of selective blockers targeting specific proteins for treatment of cardiac failure Press release
Institute of Transformative Bio-Molecules (ITbM) Exploration of small molecule compounds that regulate circadian rhythms Press release
Department of Environmental Medicine Laboratory Molecular Metabolism Medicine Research for a non-alcoholic steatohepatities (NASH) treatment drug Press release
Graduate School of Medicine, Respiratory Internal Medicine Development of novel therapeutic drugs for mutant KRAS lung cancer using cellular senescence Press release
Department of Biochemistry, Graduate School of Medicine Exploration of selective blockers targeting specific enzymes for nerve regeneration Press release
Tokyo University Graduate School of Medicine Continence Medicine course Evaluation of novel treatment mechanisms for urological diseases Press release
Gifu Pharmaceutical University Biological function analysis course Pharmacological analysis laboratory Research on therapeutic drugs for retinal diseases Press release

TMRC (subsidiary) Pipeline

Updated on 3 3, 2018

Completed
On planning
On going
Launch
Plan
Project Compound
(Generic name)
Indication Partnered party Discovery Pre-Clin, Clinical Studies NDA Approval Sales Territory Remarks
Phase 1 Phase 2 Phase 3
TM-411 TM-411
(Tamibarotene)
SY-1425 [Syros Pharmaceuticals]
AML
(Acute myelogenous leukemia)
Syros Pharmaceuticals
On going P2 (Multiple drug combination)
USA Combination with azacitidine
AML & MDS (Myelodysplastic syndrome)
On going P2 (Multiple drug combination)
USA Combination with daratumumab
Breast cancer
(BS)
On planning P2
USA Scheduled to start taking into consideration the effectiveness of AML/MDS combination test
TM-411
(Tamibarotene)
Neuroblastoma
(NB)
Ohara Pharmaceutical
On going P1
Japan
Acute promyelocytic leukemia
(APL)
Toko Pharmaceutical Industrial
NDA
China
Neutropenia
(NP)
-
Completed
USA

Because of the personal survey, there are cases where the information on this site is "different from the fact" due to business content change or misunderstanding etc.
Therefore, please do not use for investment judgment. Also, this site is not intended to solicit investment.

Advertisements